Vaxart Common Stock Total Equity vs Short Term Debt Analysis

VXRT Stock

USD 0.78 0.02 2.50%

Vaxart financial indicator trend analysis is much more than just breaking down Vaxart Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxart Inc is a good investment. Please check the relationship between Vaxart Common Stock Total Equity and its Short Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Common Stock Total Equity vs Short Term Debt

Common Stock Total Equity vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxart Inc Common Stock Total Equity account and Short Term Debt. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Vaxart's Common Stock Total Equity and Short Term Debt is -0.55. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Vaxart Inc, assuming nothing else is changed. The correlation between historical values of Vaxart's Common Stock Total Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Vaxart Inc are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock Total Equity i.e., Vaxart's Common Stock Total Equity and Short Term Debt go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Short Term Debt

Most indicators from Vaxart's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxart Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Enterprise Value is likely to gain to about 130.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.2 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	70.6M	110.4M	86.2M	44.6M
Cost Of Revenue	48.7M	3.3M	4.5M	4.3M

Total Operating Expenses Cost Of Revenue

Vaxart fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity	Common Stock
Total Assets		0.53	0.1	0.45	0.98	0.57	-0.64	-0.53	0.82	0.68	0.39	0.9	-0.1	0.7	0.42	-0.18	0.58	0.73	0.65	0.48	0.85	0.27	0.09	0.04	-0.57	-0.41
Short Long Term Debt Total	0.53		0.0	0.3	0.4	0.94	0.24	-0.89	0.05	0.87	0.71	0.17	-0.34	0.95	0.55	0.12	0.78	0.88	0.69	0.91	0.06	0.89	0.12	-0.1	-0.75	-0.67
Other Current Liab	0.1	0.0		0.77	0.08	0.02	-0.04	0.04	0.05	-0.04	-0.17	0.02	0.68	-0.08	-0.35	-0.08	0.04	0.01	0.07	-0.04	0.08	-0.03	-0.36	-0.22	0.05	0.15
Total Current Liabilities	0.45	0.3	0.77		0.43	0.37	-0.19	-0.2	0.28	0.31	0.06	0.28	0.62	0.28	-0.24	-0.14	0.43	0.23	0.3	0.27	0.33	0.14	-0.2	0.22	-0.31	-0.23
Total Stockholder Equity	0.98	0.4	0.08	0.43		0.47	-0.73	-0.37	0.87	0.61	0.32	0.93	-0.01	0.6	0.26	-0.15	0.47	0.6	0.48	0.4	0.91	0.11	0.07	0.12	-0.54	-0.36
Property Plant And Equipment Net	0.57	0.94	0.02	0.37	0.47		0.16	-0.85	0.09	0.9	0.82	0.26	-0.31	0.92	0.49	0.21	0.77	0.85	0.68	0.87	0.19	0.72	0.07	0.02	-0.74	-0.66
Net Debt	-0.64	0.24	-0.04	-0.19	-0.73	0.16		-0.13	-0.95	0.0	0.28	-0.88	-0.13	0.0	-0.04	0.34	0.08	-0.09	-0.14	0.12	-0.91	0.34	-0.01	-0.1	0.01	-0.13
Retained Earnings	-0.53	-0.89	0.04	-0.2	-0.37	-0.85	-0.13		-0.13	-0.73	-0.6	-0.26	0.4	-0.85	-0.75	0.13	-0.71	-0.95	-0.84	-0.83	-0.15	-0.83	-0.01	0.25	0.51	0.44
Cash	0.82	0.05	0.05	0.28	0.87	0.09	-0.95	-0.13		0.24	-0.1	0.95	0.04	0.28	0.21	-0.33	0.17	0.35	0.36	0.13	0.94	-0.07	0.04	0.07	-0.22	-0.05
Non Current Assets Total	0.68	0.87	-0.04	0.31	0.61	0.9	0.0	-0.73	0.24		0.76	0.38	-0.32	0.92	0.5	0.09	0.66	0.83	0.66	0.8	0.31	0.61	0.41	-0.1	-0.82	-0.83
Non Currrent Assets Other	0.39	0.71	-0.17	0.06	0.32	0.82	0.28	-0.6	-0.1	0.76		0.16	-0.52	0.71	0.48	0.52	0.56	0.63	0.51	0.5	0.1	0.4	0.2	0.0	-0.6	-0.58
Cash And Short Term Investments	0.9	0.17	0.02	0.28	0.93	0.26	-0.88	-0.26	0.95	0.38	0.16		-0.08	0.4	0.32	-0.22	0.31	0.48	0.47	0.18	0.98	-0.07	0.0	0.08	-0.3	-0.11
Net Receivables	-0.1	-0.34	0.68	0.62	-0.01	-0.31	-0.13	0.4	0.04	-0.32	-0.52	-0.08		-0.41	-0.77	-0.25	-0.24	-0.41	-0.43	-0.25	0.05	-0.33	-0.39	0.24	0.27	0.3
Common Stock Shares Outstanding	0.7	0.95	-0.08	0.28	0.6	0.92	0.0	-0.85	0.28	0.92	0.71	0.4	-0.41		0.58	0.05	0.75	0.92	0.72	0.89	0.29	0.78	0.25	-0.11	-0.81	-0.75
Non Current Liabilities Total	0.42	0.55	-0.35	-0.24	0.26	0.49	-0.04	-0.75	0.21	0.5	0.48	0.32	-0.77	0.58		-0.09	0.42	0.75	0.86	0.42	0.18	0.55	0.28	-0.41	-0.26	-0.27
Inventory	-0.18	0.12	-0.08	-0.14	-0.15	0.21	0.34	0.13	-0.33	0.09	0.52	-0.22	-0.25	0.05	-0.09		-0.06	-0.1	-0.16	-0.05	-0.21	0.0	-0.1	0.21	-0.1	-0.03
Other Current Assets	0.58	0.78	0.04	0.43	0.47	0.77	0.08	-0.71	0.17	0.66	0.56	0.31	-0.24	0.75	0.42	-0.06		0.69	0.63	0.66	0.21	0.6	-0.03	0.18	-0.68	-0.53
Other Stockholder Equity	0.73	0.88	0.01	0.23	0.6	0.85	-0.09	-0.95	0.35	0.83	0.63	0.48	-0.41	0.92	0.75	-0.1	0.69		0.86	0.81	0.37	0.75	0.11	-0.32	-0.6	-0.51
Total Liab	0.65	0.69	0.07	0.3	0.48	0.68	-0.14	-0.84	0.36	0.66	0.51	0.47	-0.43	0.72	0.86	-0.16	0.63	0.86		0.56	0.35	0.61	0.17	-0.28	-0.41	-0.38
Property Plant And Equipment Gross	0.48	0.91	-0.04	0.27	0.4	0.87	0.12	-0.83	0.13	0.8	0.5	0.18	-0.25	0.89	0.42	-0.05	0.66	0.81	0.56		0.11	0.84	0.09	-0.08	-0.7	-0.63
Total Current Assets	0.85	0.06	0.08	0.33	0.91	0.19	-0.91	-0.15	0.94	0.31	0.1	0.98	0.05	0.29	0.18	-0.21	0.21	0.37	0.35	0.11		-0.19	-0.05	0.14	-0.24	-0.04
Short Term Debt	0.27	0.89	-0.03	0.14	0.11	0.72	0.34	-0.83	-0.07	0.61	0.4	-0.07	-0.33	0.78	0.55	0.0	0.6	0.75	0.61	0.84	-0.19		0.11	-0.25	-0.55	-0.49
Intangible Assets	0.09	0.12	-0.36	-0.2	0.07	0.07	-0.01	-0.01	0.04	0.41	0.2	0.0	-0.39	0.25	0.28	-0.1	-0.03	0.11	0.17	0.09	-0.05	0.11		-0.27	-0.41	-0.7
Accounts Payable	0.04	-0.1	-0.22	0.22	0.12	0.02	-0.1	0.25	0.07	-0.1	0.0	0.08	0.24	-0.11	-0.41	0.21	0.18	-0.32	-0.28	-0.08	0.14	-0.25	-0.27		-0.07	0.04
Common Stock Total Equity	-0.57	-0.75	0.05	-0.31	-0.54	-0.74	0.01	0.51	-0.22	-0.82	-0.6	-0.3	0.27	-0.81	-0.26	-0.1	-0.68	-0.6	-0.41	-0.7	-0.24	-0.55	-0.41	-0.07		0.82
Common Stock	-0.41	-0.67	0.15	-0.23	-0.36	-0.66	-0.13	0.44	-0.05	-0.83	-0.58	-0.11	0.3	-0.75	-0.27	-0.03	-0.53	-0.51	-0.38	-0.63	-0.04	-0.49	-0.7	0.04	0.82

Click cells to compare fundamentals

Vaxart Account Relationship Matchups

Vaxart fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Short Long Term Debt Total	2.3M	7.2M	13.0M	21.7M	26.5M	28.4M
Other Current Liab	2.9M	3.4M	836K	8.2M	5.6M	9.6M
Total Current Liabilities	9.2M	11.8M	10.8M	17.9M	13.7M	17.6M
Total Stockholder Equity	13.0M	123.4M	187.5M	110.6M	57.8M	89.3M
Property Plant And Equipment Net	2.2M	8.3M	19.8M	41.3M	36.6M	27.5M
Net Debt	(11.2M)	(119.7M)	(130.7M)	(22.3M)	(8.2M)	(8.7M)
Retained Earnings	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(409.6M)	(389.1M)
Cash	13.5M	126.9M	143.7M	44.0M	34.8M	52.2M
Non Current Assets Total	19.4M	24.1M	52.0M	54.4M	46.3M	40.4M
Non Currrent Assets Other	141K	372K	890K	3.6M	926K	879.7K
Cash And Short Term Investments	13.5M	126.9M	166.5M	93.7M	39.7M	61.2M
Net Receivables	3.6M	334K	71K	20K	3.0M	2.9M
Common Stock Shares Outstanding	21.6M	88.3M	121.5M	127.7M	144.8M	152.1M
Liabilities And Stockholders Equity	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Non Current Liabilities Total	14.9M	17.4M	22.9M	25.3M	20.3M	27.5M
Other Current Assets	453K	1.3M	2.6M	3.7M	2.8M	4.6M
Other Stockholder Equity	129.6M	272.3M	406.9M	438.0M	467.4M	490.7M
Total Liab	24.1M	29.2M	33.6M	43.3M	34.0M	44.6M
Property Plant And Equipment Gross	2.2M	8.3M	19.8M	15.6M	43.4M	24.7M
Total Current Assets	17.6M	128.5M	169.2M	99.5M	45.5M	43.3M
Accumulated Other Comprehensive Income	(1.6M)	(459K)	(74K)	(299K)	(1K)	(1.1K)
Short Term Debt	841K	2.1M	1.0M	2.2M	6.5M	6.8M
Intangible Assets	17.1M	15.4M	10.6M	5.0M	4.3M	4.1M
Accounts Payable	852K	2.1M	3.9M	5.5M	1.6M	1.5M
Common Stock Total Equity	714K	4.8M	11K	13K	11.7K	11.1K
Common Stock	714K	5K	11K	13K	15K	14.3K
Current Deferred Revenue	4.6M	4.2M	5.1M	2M	1.8M	1.7M
Other Liab	13.4M	14.9M	10.9M	5.9M	6.7M	7.9M
Net Tangible Assets	13.0M	123.4M	187.5M	110.6M	127.2M	67.4M
Other Assets	141K	372K	890K	3.6M	4.1M	4.3M
Retained Earnings Total Equity	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(294.4M)	(279.7M)
Capital Surpluse	124.8M	272.3M	406.9M	438.0M	503.7M	528.9M
Property Plant Equipment	210K	1.5M	6.6M	15.6M	17.9M	18.8M

Pair Trading with Vaxart

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxart position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxart will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vaxart Stock

0.68	EGRX	Eagle Pharmaceuticals Upward Rally	Pair Corr
0.77	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.82	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr

Moving against Vaxart Stock

0.59	MAIA	MAIA Biotechnology	Pair Corr
0.58	INCR	INC Research Holdings	Pair Corr
0.58	PAHC	Phibro Animal Health Fiscal Year End 4th of September 2024	Pair Corr
0.56	DCPH	Deciphera Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Vaxart could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxart when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxart - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxart Inc to buy it.

The correlation of Vaxart is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxart moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxart Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vaxart can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC